Table 3. Molecular and survival outcomes... | American Society of Hematology

Table 3.

Molecular and survival outcomes according to Sokal score at diagnosis: ENESTnd randomized trial results

Score	Imatinib 400 mg once daily, %			Nilotinib 300 mg twice daily, %
Score	CCyR*	MR3†	5-y OS	CCyR*	MR3†	5-y OS
Low	90	62.5	100	91	76.7	97
Intermediate	85	54.5	88.5	87	75.2	93.8
High	72	38.5	84.2	81	66.7	88.8

Score	Imatinib 400 mg once daily, %			Nilotinib 300 mg twice daily, %
Score	CCyR*	MR3†	5-y OS	CCyR*	MR3†	5-y OS
Low	90	62.5	100	91	76.7	97
Intermediate	85	54.5	88.5	87	75.2	93.8
High	72	38.5	84.2	81	66.7	88.8

Adapted with permission.¹⁶

OS, overall survival.

Cumulative response at 2 years.

Cumulative response at 3 years.